Review



human gc cell lines snu 16  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    ATCC human gc cell lines snu 16
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Human Gc Cell Lines Snu 16, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 396 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pmc13008354-148-0-5?v=ATCC
    Average 96 stars, based on 396 article reviews
    human gc cell lines snu 16 - by Bioz Stars, 2026-07
    96/100 stars

    Images

    1) Product Images from "Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer"

    Article Title: Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer

    Journal: eLife

    doi: 10.7554/eLife.104060

    Sensitivity of KATOIII and SNU-16 to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Figure Legend Snippet: Sensitivity of KATOIII and SNU-16 to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .

    Techniques Used: Concentration Assay, Incubation, Western Blot

    BALB/c nude mice were injected with 1×10 7 SNU-16 cancer cells and received different formulations by oral gavage every day upon tumor volumes reached 100–150 mm 3 . ( A ) Schematic of SHP099 and AZD4547 therapeutic schedule in FGFR2 -amplified SNU-16 subcutaneous xenograft model. ( B ) Representative images of tumors (n=5). ( C ) Tumor volumes (n=5; two-way ANOVA), ( D ) tumor weights (n=5; one-way ANOVA) and ( E ) body weights (n=5; two-way ANOVA) of different groups. ( F ) Tumors were harvested 6 hours after the last dose of drugs, and cell lysates from tumor tissues were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 4—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 4—source data 2. Original file for western blots displayed in .
    Figure Legend Snippet: BALB/c nude mice were injected with 1×10 7 SNU-16 cancer cells and received different formulations by oral gavage every day upon tumor volumes reached 100–150 mm 3 . ( A ) Schematic of SHP099 and AZD4547 therapeutic schedule in FGFR2 -amplified SNU-16 subcutaneous xenograft model. ( B ) Representative images of tumors (n=5). ( C ) Tumor volumes (n=5; two-way ANOVA), ( D ) tumor weights (n=5; one-way ANOVA) and ( E ) body weights (n=5; two-way ANOVA) of different groups. ( F ) Tumors were harvested 6 hours after the last dose of drugs, and cell lysates from tumor tissues were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 4—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 4—source data 2. Original file for western blots displayed in .

    Techniques Used: Injection, Amplification, Western Blot

    ( A ) Overview of FGFR2 alterations individually in GC patients from Nanjing Drum Tower hospital cohort. ( B ) PD-L1 mRNA expression levels were analyzed between FGFR2 -amplified group (n=13) and FGFR2 -unamplified group (n=250) from TCGA-STAD cohort (Welch’s t -test). ( C ) Proportions of MSI-H or MSS in FGFR2 -amplified group (n=12) and FGFR2 -unamplified group (n=237) from TCGA-STAD cohort (Fisher’s exact test). Human peripheral blood mononuclear cells (PBMCs) were incubated with different administrations in the presence of 0.25 μg/ml human anti-CD3 and 1 μg/ml human anti-CD28. Proportions of ( D ) IFN-γ/CD8+ cells were detected by flow cytometry assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( E ) Expression levels of IFN-γ in cellular supernatant were measured by Cytometric Bead Array (CBA) assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( F ) Cell viability of human PBMCs after 48 hours of drugs incubation (n=4; one-way ANOVA). ( G, H ) After 48 hours of advance drugs stimulation in human PBMCs, cytotoxicities of human PBMCs against SNU-16 at different E:T ratios of 10:1, 20:1, 40:1 were analyzed by flow cytometry assay after CFSE/PI staining (n=3; two-way ANOVA). Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by Welch’s t -test, Fisher’s exact test, ordinary one-way ANOVA or two-way ANOVA.
    Figure Legend Snippet: ( A ) Overview of FGFR2 alterations individually in GC patients from Nanjing Drum Tower hospital cohort. ( B ) PD-L1 mRNA expression levels were analyzed between FGFR2 -amplified group (n=13) and FGFR2 -unamplified group (n=250) from TCGA-STAD cohort (Welch’s t -test). ( C ) Proportions of MSI-H or MSS in FGFR2 -amplified group (n=12) and FGFR2 -unamplified group (n=237) from TCGA-STAD cohort (Fisher’s exact test). Human peripheral blood mononuclear cells (PBMCs) were incubated with different administrations in the presence of 0.25 μg/ml human anti-CD3 and 1 μg/ml human anti-CD28. Proportions of ( D ) IFN-γ/CD8+ cells were detected by flow cytometry assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( E ) Expression levels of IFN-γ in cellular supernatant were measured by Cytometric Bead Array (CBA) assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( F ) Cell viability of human PBMCs after 48 hours of drugs incubation (n=4; one-way ANOVA). ( G, H ) After 48 hours of advance drugs stimulation in human PBMCs, cytotoxicities of human PBMCs against SNU-16 at different E:T ratios of 10:1, 20:1, 40:1 were analyzed by flow cytometry assay after CFSE/PI staining (n=3; two-way ANOVA). Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by Welch’s t -test, Fisher’s exact test, ordinary one-way ANOVA or two-way ANOVA.

    Techniques Used: Expressing, Amplification, Incubation, Flow Cytometry, Staining



    Similar Products

    human gc cell lines snu 16  (ATCC)
    96
    ATCC human gc cell lines snu 16
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Human Gc Cell Lines Snu 16, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pmc13008354-148-0-5?v=ATCC
    Average 96 stars, based on 1 article reviews
    human gc cell lines snu 16 - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    human gc cell lines snu-16 #icell-h430  (iCell Gene Therapeutics)
    90
    iCell Gene Therapeutics human gc cell lines snu-16 #icell-h430
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Human Gc Cell Lines Snu 16 #Icell H430, supplied by iCell Gene Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pm39748101-47-10-15?v=iCell+Gene+Therapeutics
    Average 90 stars, based on 1 article reviews
    human gc cell lines snu-16 #icell-h430 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    human gc cell line  (ATCC)
    96
    ATCC human gc cell line
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Human Gc Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pm38824966-85-0-14?v=ATCC
    Average 96 stars, based on 1 article reviews
    human gc cell line - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    cell culture human gc cell lines  (ATCC)
    96
    ATCC cell culture human gc cell lines
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Cell Culture Human Gc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pm38184692-52-3-21?v=ATCC
    Average 96 stars, based on 1 article reviews
    cell culture human gc cell lines - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier
    human gc cell lines  (ATCC)
    96
    ATCC human gc cell lines
    Sensitivity of KATOIII <t>and</t> <t>SNU-16</t> to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .
    Human Gc Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+gc+cell+lines+snu+16/pm36918782-44-0-14?v=ATCC
    Average 96 stars, based on 1 article reviews
    human gc cell lines - by Bioz Stars, 2026-07
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Sensitivity of KATOIII and SNU-16 to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .

    Journal: eLife

    Article Title: Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer

    doi: 10.7554/eLife.104060

    Figure Lengend Snippet: Sensitivity of KATOIII and SNU-16 to ( A ) SHP099, ( B ) AZD4547, or combination therapy with different concentration gradients (n=4; two-way ANOVA). Effects of different treatments on cell apoptosis of ( C ) KATOIII and ( D ) SNU-16 after 48-hour drugs incubation (n=3; one-way ANOVA). ( E ) KATOIII and ( F ) SNU-16 were incubated with vehicle, SHP099 10 μM, AZD4547 3 nM or combination therapies for 1 hour or 48 hours, then cell lysates were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-p38 and total-p38, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 2—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 2—source data 2. Original file for western blots displayed in .

    Article Snippet: Human GC cell lines SNU-16 (ATCC CRL-5974), MKN45 (KANGBAI CBP60488), NUGC4 (KANGBAI CBP60493), HGC27 (KANGBAI CBP60480), and SNU601 (KANGBAI CBP60507) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).

    Techniques: Concentration Assay, Incubation, Western Blot

    BALB/c nude mice were injected with 1×10 7 SNU-16 cancer cells and received different formulations by oral gavage every day upon tumor volumes reached 100–150 mm 3 . ( A ) Schematic of SHP099 and AZD4547 therapeutic schedule in FGFR2 -amplified SNU-16 subcutaneous xenograft model. ( B ) Representative images of tumors (n=5). ( C ) Tumor volumes (n=5; two-way ANOVA), ( D ) tumor weights (n=5; one-way ANOVA) and ( E ) body weights (n=5; two-way ANOVA) of different groups. ( F ) Tumors were harvested 6 hours after the last dose of drugs, and cell lysates from tumor tissues were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 4—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 4—source data 2. Original file for western blots displayed in .

    Journal: eLife

    Article Title: Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer

    doi: 10.7554/eLife.104060

    Figure Lengend Snippet: BALB/c nude mice were injected with 1×10 7 SNU-16 cancer cells and received different formulations by oral gavage every day upon tumor volumes reached 100–150 mm 3 . ( A ) Schematic of SHP099 and AZD4547 therapeutic schedule in FGFR2 -amplified SNU-16 subcutaneous xenograft model. ( B ) Representative images of tumors (n=5). ( C ) Tumor volumes (n=5; two-way ANOVA), ( D ) tumor weights (n=5; one-way ANOVA) and ( E ) body weights (n=5; two-way ANOVA) of different groups. ( F ) Tumors were harvested 6 hours after the last dose of drugs, and cell lysates from tumor tissues were immunoblotted for phospho-FGFR and total-FGFR2, phospho-SHP2 and total-SHP2, phospho-Erk and total-Erk, phospho-AKT and total-AKT, and phospho-mTOR and total-mTOR. Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by ordinary one-way ANOVA or two-way ANOVA. Figure 4—source data 1. PDF file containing original western blots for , indicating the relevant bands. Figure 4—source data 2. Original file for western blots displayed in .

    Article Snippet: Human GC cell lines SNU-16 (ATCC CRL-5974), MKN45 (KANGBAI CBP60488), NUGC4 (KANGBAI CBP60493), HGC27 (KANGBAI CBP60480), and SNU601 (KANGBAI CBP60507) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).

    Techniques: Injection, Amplification, Western Blot

    ( A ) Overview of FGFR2 alterations individually in GC patients from Nanjing Drum Tower hospital cohort. ( B ) PD-L1 mRNA expression levels were analyzed between FGFR2 -amplified group (n=13) and FGFR2 -unamplified group (n=250) from TCGA-STAD cohort (Welch’s t -test). ( C ) Proportions of MSI-H or MSS in FGFR2 -amplified group (n=12) and FGFR2 -unamplified group (n=237) from TCGA-STAD cohort (Fisher’s exact test). Human peripheral blood mononuclear cells (PBMCs) were incubated with different administrations in the presence of 0.25 μg/ml human anti-CD3 and 1 μg/ml human anti-CD28. Proportions of ( D ) IFN-γ/CD8+ cells were detected by flow cytometry assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( E ) Expression levels of IFN-γ in cellular supernatant were measured by Cytometric Bead Array (CBA) assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( F ) Cell viability of human PBMCs after 48 hours of drugs incubation (n=4; one-way ANOVA). ( G, H ) After 48 hours of advance drugs stimulation in human PBMCs, cytotoxicities of human PBMCs against SNU-16 at different E:T ratios of 10:1, 20:1, 40:1 were analyzed by flow cytometry assay after CFSE/PI staining (n=3; two-way ANOVA). Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by Welch’s t -test, Fisher’s exact test, ordinary one-way ANOVA or two-way ANOVA.

    Journal: eLife

    Article Title: Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2 -amplified gastric cancer

    doi: 10.7554/eLife.104060

    Figure Lengend Snippet: ( A ) Overview of FGFR2 alterations individually in GC patients from Nanjing Drum Tower hospital cohort. ( B ) PD-L1 mRNA expression levels were analyzed between FGFR2 -amplified group (n=13) and FGFR2 -unamplified group (n=250) from TCGA-STAD cohort (Welch’s t -test). ( C ) Proportions of MSI-H or MSS in FGFR2 -amplified group (n=12) and FGFR2 -unamplified group (n=237) from TCGA-STAD cohort (Fisher’s exact test). Human peripheral blood mononuclear cells (PBMCs) were incubated with different administrations in the presence of 0.25 μg/ml human anti-CD3 and 1 μg/ml human anti-CD28. Proportions of ( D ) IFN-γ/CD8+ cells were detected by flow cytometry assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( E ) Expression levels of IFN-γ in cellular supernatant were measured by Cytometric Bead Array (CBA) assay after 24 hours of drugs incubation (n=3; one-way ANOVA). ( F ) Cell viability of human PBMCs after 48 hours of drugs incubation (n=4; one-way ANOVA). ( G, H ) After 48 hours of advance drugs stimulation in human PBMCs, cytotoxicities of human PBMCs against SNU-16 at different E:T ratios of 10:1, 20:1, 40:1 were analyzed by flow cytometry assay after CFSE/PI staining (n=3; two-way ANOVA). Data are shown as mean ± SEM. ns, not significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. p-Values are determined by Welch’s t -test, Fisher’s exact test, ordinary one-way ANOVA or two-way ANOVA.

    Article Snippet: Human GC cell lines SNU-16 (ATCC CRL-5974), MKN45 (KANGBAI CBP60488), NUGC4 (KANGBAI CBP60493), HGC27 (KANGBAI CBP60480), and SNU601 (KANGBAI CBP60507) were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China).

    Techniques: Expressing, Amplification, Incubation, Flow Cytometry, Staining